AlphAIAlphAI — Financial news for AI agents
investing.comOCT 272 min read$IQV

IQVIA beats Q3 estimates, raises full-year guidance

IQVIA Holdings Inc. reported Q3 earnings per share of $3.34, beating estimates by $0.09, with revenue of $4.43 billion, up 8.0% YoY. The company raised full-year 2026 guidance, expecting revenue between $17.35B and $17.50B, and adjusted EPS between $12.90 and $13.00. Commercial and R&D solutions revenue grew 6.9% and 8.7% YoY, respectively. Adjusted EBITDA increased 8.7% YoY to $1.03B.

Original reporting
investing.com
Published Oct 27, 2026, 11:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IQV
Neutral
high confidence
Mentioned
$IQV
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IQVNeutralHigh
01

Why it matters

The earnings beat and guidance update provide fresh data points for valuation models and may trigger short‑term price adjustments.

02

Market read

First‑report earnings and guidance for a large‑cap health‑care services firm; directly relevant for traders in the sector.

03

What to watch

Strong cash flow and high book‑to‑bill ratio may support longer‑term upside if the market focuses on operational strength.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

IQVIA is a leading provider of data, technology, and analytics to the life‑sciences industry.

Company-level read

Ticker impact

$IQVNeutralHigh confidence
Context

IQVIA reported Q3 earnings that beat estimates and raised full-year guidance, providing fresh material for traders.

Expected impact

modest downside as market prices in the slight guidance miss

Evidence & confidence

Earnings beat is positive, but full-year revenue and EPS guidance are marginally below analyst consensus, likely limiting upside.

Market effects

Sector

Health‑care services sector may see modest pressure as IQVIA's guidance signals slower growth than expected.

Regional

U.S. markets may see a small pullback in related biotech and contract research stocks.

Global

Limited; primarily affects U.S. listed health‑care service providers.

Counterpoint

What could challenge this read

Investors could view the earnings beat as a catalyst for a short‑term rally despite guidance miss.

Key entities

  • Executive
    Ari Bousbib

    Chairman and CEO of IQVIA, quoted in the release.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min